Brazil studies dx needs of hypertension, diabetes
This article was originally published in Clinica
Executive Summary
Brazil is about to launch a groundbreaking multicentre study into the evolution of hypertension and diabetes, with a view to assessing the importance of early diagnosis. From January 2006, 15,000 people are to be monitored continuously "over the next 20 or even 30 years". The programme will be co-funded primarily by the ministries of health and science and technology and has been given a budget of R$22.6m (US$9.6m) in 2006-08.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.